Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Yafei Liu, Wai Tuck Soh, Jun-ichi Kishikawa, et al.
Cell (2021) Vol. 184, Iss. 13, pp. 3452-3466.e18
Open Access | Times Cited: 258

Showing 1-25 of 258 citing articles:

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Cell (2022) Vol. 185, Iss. 3, pp. 467-484.e15
Open Access | Times Cited: 921
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Dapeng Li, Robert J. Edwards, Kartik Manne, et al.
Cell (2021) Vol. 184, Iss. 16, pp. 4203-4219.e32
Open Access | Times Cited: 277
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 233
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, et al.
Cell Reports (2021) Vol. 38, Iss. 2, pp. 110218-110218
Open Access | Times Cited: 180
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75
Yunlong Cao, Weiliang Song, Lei Wang, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 11, pp. 1527-1539.e5
Open Access | Times Cited: 158
The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation
Maaran Michael Rajah, Annie Bernier, Julian Buchrieser, et al.
Journal of Molecular Biology (2021) Vol. 434, Iss. 6, pp. 167280-167280
Open Access | Times Cited: 153
SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment
Dapeng Li, Gregory D. Sempowski, Kevin O. Saunders, et al.
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 1-16
Closed Access | Times Cited: 130
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Zijun Wang, Frauke Muecksch, Alice Cho, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 998-1012.e8
Open Access | Times Cited: 128
Neutralizing antibodies for the prevention and treatment of COVID-19
Lanying Du, Yang Yang, Xiujuan Zhang
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 10, pp. 2293-2306
Open Access | Times Cited: 117
A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
Guillaume Beaudoin-Bussières, Yaozong Chen, Irfan Ullah, et al.
Cell Reports (2022) Vol. 38, Iss. 7, pp. 110368-110368
Open Access | Times Cited: 114
SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Kevin W. Ng, Nikhil Faulkner, Katja Finsterbusch, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 655
Open Access | Times Cited: 85
The puzzling mutational landscape of the SARS‐2‐variant Omicron
Jacques Fantini, Nouara Yahi, Philippe Colson, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2019-2025
Open Access | Times Cited: 77
Cell–cell communication: new insights and clinical implications
Jimeng Su, Ying Song, Zhipeng Zhu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 22
Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein
Zhuocheng Yao, Lin Zhang, Yuange Duan, et al.
Journal of Infection (2024) Vol. 88, Iss. 3, pp. 106121-106121
Open Access | Times Cited: 14
SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 96
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 71
Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages
Tadashi Maemura, Makoto Kuroda, Tammy Armbrust, et al.
mBio (2021) Vol. 12, Iss. 5
Open Access | Times Cited: 69
Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
Cillian Gartlan, Tom Tipton, Francisco J. Salguero, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 56
Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects
Zhan Zhang, Qi Shen, Haocai Chang
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 55
Adverse effects of COVID-19 vaccines and measures to prevent them
Kenji Yamamoto
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 51
Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection
Kosuke Okuya, Takanari Hattori, Takeshi Saito, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 42
SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity
Bo Meng, Rawlings Datir, Jinwook Choi, et al.
Cell Reports (2022) Vol. 40, Iss. 7, pp. 111220-111220
Open Access | Times Cited: 40
Role of the humoral immune response during COVID-19: guilty or not guilty?
Melyssa Yaugel-Novoa, Thomas Bourlet, Stéphane Paul
Mucosal Immunology (2022) Vol. 15, Iss. 6, pp. 1170-1180
Open Access | Times Cited: 38
Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells
Jun Shimizu, Tadahiro Sasaki, Ritsuko Koketsu, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top